Protecting vision, preserving the person — the promise of ocular-sparing oncology.
Clinical Trials
Dive into the heart of innovation with our “Clinical Trials” subcategory, where we unveil the dynamic world of oncology research in real-time. Discover the latest developments and breakthroughs in cancer treatment as we explore ongoing clinical trials and their potential impact on patient care. Gain insights into the rigorous process of testing novel therapies, uncover promising treatment options, and learn how these trials contribute to advancing the field of oncology. Stay informed and be part of the journey towards more effective and compassionate cancer care.
Details once dismissed as trivial—like timing—can quietly reshape cancer care.
Sometimes restraint is the wiser choice — half of patients are cured with PD-1 alone.
When innovation meets immune activation, new possibilities emerge for melanoma care.
Targeting PRAME with TCR-T cell therapy may mark a new era for immunotherapy in melanoma and beyond.
When immune therapy clears cancer, the real question for resectable tumors becomes: Do we still need to resect?
From early-stage to brain metastases, ASCO’s latest melanoma abstracts spotlight the growing power of targeted and immune-based therapies across disease stages.
Five groundbreaking trials from the ASCO Plenary are transforming cancer care—ushering in biomarker-led immunotherapy across multiple disease types.
For years, the treatment of esophageal carcinoma has been a subject of debate, with varying multimodal approaches tailored based on tumor location and staging. Traditionally, gastric cancer patients often underwent perioperative FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) followed by surgical resection. Meanwhile, esophageal carcinoma patients were typically treated with neoadjuvant chemoradiotherapy (CROSS regimen: carboplatin/paclitaxel with radiation) followed by surgery or upfront chemotherapy …
On December 20, 2024, the FDA granted accelerated approval for a groundbreaking new treatment approach for patients with metastatic colorectal cancer (mCRC) harboring the BRAF V600E mutation. The newly approved regimen combines encorafenib (Braftovi) with cetuximab and mFOLFOX6 (a chemotherapy regimen consisting of fluorouracil, leucovorin, and oxaliplatin). This marks a pivotal step forward in the …